会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • NUCLEIC ACID-CONTAINING COMPLEX
    • 含有核酸的复合物
    • US20090203768A1
    • 2009-08-13
    • US11740200
    • 2007-04-25
    • Hidezo MoriYasuhiko TabataKiyoshi AndoEtsuro TanakaHarukazu IsekiHiromi SakamotoNaoto FukuyamaHirofumi Kasahara
    • Hidezo MoriYasuhiko TabataKiyoshi AndoEtsuro TanakaHarukazu IsekiHiromi SakamotoNaoto FukuyamaHirofumi Kasahara
    • A61K31/7088A61P35/00A61K9/14
    • A61K47/643
    • A nucleic acid-containing complex, containing a nucleic acid and a biodegradable polymer, especially a positively-charged water-insoluble biodegradable polymer, is disclosed. The complex has excellent properties of sustainedly releasing a desired nucleic acid, especially DNA, to a site in need of a treatment. Since the complex can be taken up to phagocytes such as macrophages and delivered specifically to the target site, the function of the nucleic acid can be exhibited in a target site specific manner, and thus more specific gene therapy can be achieved. The complex has no adverse effects, such as occurrence of recombinants or toxicity which could be caused by using a virus vector such as adenovirus, or liposome. Thus, the complex is particularly preferable for the field of gene therapy. Furthermore, the complex enhances the biological effect of the nucleic acid introduced into the cells, allowing a gene therapy with a lower dose of nucleic acids.
    • 公开了含有核酸和可生物降解的聚合物,特别是带正电的水不溶性可生物降解聚合物的含核酸复合物。 该复合物具有将期望的核酸,特别是DNA持续释放到需要治疗的部位的优异性质。 由于复合物可以被吸收到诸如巨噬细胞的吞噬细胞并且特异性递送到靶位点,因此可以以靶位点特异性方式显示核酸的功能,从而可以实现更具体的基因治疗。 该复合物没有不利影响,例如可能由使用病毒载体如腺病毒或脂质体引起的重组体或毒性的发生。 因此,该复合物对于基因治疗领域是特别优选的。 此外,复合物增强引入细胞的核酸的生物学效应,允许用较低剂量的核酸进行基因治疗。
    • 7. 发明授权
    • Method to enhance healing of sternum after sternotomy
    • 胸骨切开后胸骨愈合的方法
    • US06732738B1
    • 2004-05-11
    • US09687379
    • 2000-10-13
    • Masashi KomedaYasuhiko Tabata
    • Masashi KomedaYasuhiko Tabata
    • A61B1900
    • A61K38/1825
    • There are disclosed a method to enhance sternal treatment after sternotomy with or without removal of at least one of thoracic arteries which comprises applying an agent for the treatment of sternum after sternotomy to or at around the sternum, wherein the agent comprises at least one selected from the group consisting of an angiogenetic factor, an osteogenetic factor and their analogues such as bFGF, aFGF, TGF &bgr;, VEGF, HGF, BMP, PDGF, TGF &agr;, other cytokines or gene as an effective ingredient and an agent to be used for the method; and an agent to enhance healing of or treating sternum after sternotomy comprising the same.
    • 公开了一种在胸骨切开术之后加强或不去除胸廓动脉中的至少一种来增强胸骨治疗的方法,其包括在胸骨切开后或在胸骨周围施用用于治疗胸骨的药剂,其中所述药剂包含选自以下的至少一种: 由血管生成因子,成骨因子及其类似物组成的组,例如bFGF,aFGF,TGFβ,VEGF,HGF,BMP,PDGF,TGFα,其他细胞因子或基因作为有效成分,以及用于 方法; 以及用于增强胸骨切开术后胸骨愈合或治疗胸骨的药剂。